Autoantibody against activating transcription factor-2 in patients with systemic sclerosis

Y. Akiyama, F. Ogawa, Y. Iwata, K. Komura, T. Hara, E. Muroi, S. J. Bae, M. Takenaka, K. Shimizu, M. Hasegawa, M. Fujimoto, S. Sato

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Objective: To determine the prevalence and clinical correlation of autoantibody to activating transcription factor (ATF)-2, a transcription factor of ATF/CREB family, in patients with systemic sclerosis (SSc). Methods: Anti-ATF-2 Ab was examined by ELISA and immunoblotting using human recombinant ATF-2. ATF-2 activity to bind target DNA was evaluated by ELISA using a plate coated with oligonucleotide containing the consensus binding site for ATF-2. Results: IgG anti-ATF-2 Ab levels in SSc patients (n=69) were significantly higher than those in normal controls (n=26). SSc patients positive for IgG anti-ATF-2 Ab had significantly longer disease duration, more frequent presence of decreased %VC and %DLco, and elevated levels of serum IgG, serum IgA, and erythrocyte sedimentation rates than those negative. More-over, IgG anti-ATF-2 Ab levels correlated inversely with %VC or %DLco. The presence of anti-ATF-2 Ab in SSc patients was confirmed by immunoblotting analysis. IgG isolated from serum samples of SSc patients positive for IgG anti-ATF-2 Ab by ELISA slightly but significantly inhibited ATF-2 activity compared with normal controls. Conclusions: These results suggest that anti-ATF-2 Ab is a new autoantibody in SSc and that it serves as a novel serological marker for inflammation and lung involvement in SSc.

Original languageEnglish
Pages (from-to)751-757
Number of pages7
JournalClinical and Experimental Rheumatology
Volume27
Issue number5
Publication statusPublished - 2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Autoantibody against activating transcription factor-2 in patients with systemic sclerosis'. Together they form a unique fingerprint.

Cite this